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Abstract: The use of antibody induction after kidney transplantation has increased from 
25% to 63% in the past decade and roughly one half of the induction agent used is anti-
interleukin-2 receptor antibody (IL-2RA, ie, basiliximab or daclizumab). When combined with 
calcineurin inhibitor (CNI)-based immunosuppression, IL-2RAs have been shown to reduce 
the incidence of acute rejection, one of the predictors of poor graft survival, without increasing 
risks of infections and malignancies in kidney transplantation. For low-immunological-risk 
patients, IL-2RAs, as compared with lymphocyte-depleting antibodies, are equally efficacious 
and have better safety profiles. For high-risk patients, however, IL-2RAs may be inferior to 
lymphocyte-depleting antibodies for the prophylaxis of acute rejection. In an effort to reduce 
toxicities of other immunosuppressive medications without increasing the risk of acute rejection 
and chronic graft loss, IL-2RAs have often been combined with steroid- and CNI-sparing 
immunosuppression protocols. More data support the benefits of early steroid withdrawal with 
IL-2RA in low-risk patients, but preferred induction therapy for high-risk patients has yet to 
be determined. Although CNI-sparing protocols with IL-2RA may preserve renal function and 
improve long-term survival in selected patients, further studies are needed to identify those 
who benefit most from this strategy.
Keywords: basiliximab, daclizumab, interleukin-2 receptor antagonist, kidney transplantation, 
monoclonal antibody
Introduction
Acute rejection episodes are one of the risk factors of developing chronic allograft 
injury and significantly reduce the long-term survival rates.1–3 New and more potent 
immunosuppressive medications have reduced incidence of acute rejection and 
improved short-term graft survival, but they have not greatly enhanced long-term 
outcomes. One of the reasons for this observation may be the adverse effects of 
immunosuppressive medication that may contribute to graft dysfunction as well as 
mortality and morbidity of transplant patients; eg, calcineurin inhibitors (CNIs) cause 
acute and chronic nephrotoxicity and corticosteroids increase cardiovascular and other 
risk factors.4,5 Immunosuppression agents can also be associated with infections and 
malignancies, which affect long-term patient survival.6
Because interleukin-2 (IL-2) plays a critical role in T-cell activation and 
proliferation, antibodies against α subunit (CD25) of IL-2 receptor (IL-2R) have 
been tested in animal and human models.7–9 Murine monoclonal antibodies to CD25 
significantly reduce acute rejection episodes, but the high immunogenicity and short 
half-life of these antibodies limited their clinical use.7,10 To overcome these problems, 
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chimeric (basiliximab) and humanized (daclizumab) murine 
antibodies to CD25 have been developed. These agents have 
a high affinity and specificity for CD25 on the surface of 
activated T-cells and inhibit IL-2-mediated activation and 
proliferation of T-cells in transplant patients, aiming at a 
low acute rejection rate without affecting the pre-existing 
immune responses.
In this article we review the studies using anti-IL-2R 
antibody (IL-2RA) induction in renal transplantation, 
emphasizing the prevention of acute rejection in different 
protocols. We also examined the efficacy and safety of 
IL-2RA in combination with a reduction or avoidance of 
corticosteroids and CNIs, and compared IL-2RAs with 
lymphocyte-depleting monoclonal and polyclonal antibodies 
for induction therapy. Studies using IL-2RA for treatment 
of established rejection episodes are not included in this 
review.
Dosage regimens  
and pharmacological properties
In phase III studies, two doses of basiliximab (20 mg each) 
were given on day 0 and day 4,11,12 which saturates IL-2 
Rα on the circulating lymphocytes for 4–6 weeks. Because 
of poor correlations between body weight and distribu-
tion volume or clearance, weight-adjusted dosing is not 
recommended for basiliximab.13,14 Dosage modification 
is required for pediatric patients weighing 35 kg, 
who should receive two doses of 10 mg each.15 On the 
contrary, phase III studies of daclizumab was conducted 
with a bodyweight-adjusted dose: 1 mg/kg once every two 
weeks for a total of five doses with cyclosporine (CsA)-
based triple16 or dual17 maintenance immunosuppression; 
this suppresses IL-2R for up to four months after renal 
transplantation.16 Subsequently, limited doses regimens 
(mainly two doses, at the time of transplant and 10–14 days 
thereafter) were tested with concomitant use of more 
potent baseline immunosuppression (eg, tacrolimus [TAC] 
and/or mycophenolate mofetil [MMF]).18–21 Two doses of 
daclizumab were shown to be sufficient to block IL-2Rα 
for more than 10 weeks.19 A smaller study demonstrated 
one dose (2 mg/kg on day 0) and two doses (2 mg/kg on 
day 0 and 1 mg/kg on day 14) of daclizumab saturates the 
IL-2Rα on the circulating lymphocytes for up to 42 days 
and 70 days, respectively.20
Because 90% of daclizumab and 75% of basiliximab 
are human immunoglobulin G (IgG), pharmacokinetic 
parameters are similar to exogenous human IgG antibodies. 
Both basiliximab and daclizumab have a small volume 
distribution in the central component (2.5–5.0 L), and 
exhibit a low total body clearance (10–40 mL/hr). Unlike 
murine monoclonal antibodies, both chimeric and humanized 
antibodies have prolonged serum half-lives, seven days 
for basiliximab and 20 days for daclizumab, in adult renal 
transplant patients.13–16,20,22,23 Limited data suggest drug 
interaction and pharmacokinetic alteration with CsA, TAC, 
azathioprine, and MMF.24–26 Anti-idiotypic antibody develop-
ment against the murine portion of these antibodies are rare 
owing to low immunogenicity.22,27
IL-2RA with CsA-based dual  
or triple therapy
Following phase I/II studies by Amlot and Kovarik and 
colleagues,13,27 the clinical efficacy and safety of basiliximab 
induction were evaluated with baseline immunosuppression 
consisting of cyclosporine microemulsion (CsA-ME) and 
steroids in two randomized, double-blind, placebo-controlled 
multicenter phase III trials.11,12 International Study Group 
(Europe/Canada) demonstrated significant reduction of 
clinical and biopsy-proven acute rejection (BPAR) six months 
after deceased donor kidney transplantation (34% vs 52%, 
P  0.001 and 30% vs 44%, P = 0.012, respectively).11 The 
incidence of steroid-resistant first rejection episodes that 
required antibody therapy was also significantly lower in the 
basiliximab group (10% vs 23%, P  0.001). The incidence 
of infection and other adverse events was similar in the two 
treatment groups. The acute tolerability of basiliximab was 
excellent, with no evidence of cytokine-release syndrome. 
A US trial of living or deceased donor kidney transplantation 
complied with these findings, showing significant reduction 
of rejection episodes: 38% vs 55% (P = 0.001) for clinical 
rejection and 35% vs 49% (P = 0.009) for BPAR at 
12 months.12 The rates of infection and other adverse events 
were similar. In both trials, the amount of steroids required 
was significantly lower in patients treated with basiliximab 
than in patients treated with placebo (0.56 vs 0.93 mg/kg/day, 
P  0.00111 and 0.59 vs 0.78 mg/kg/day, P = 0.02,12 both 
at four weeks post-transplant). Of note, only the US trial 
demonstrated better renal function at 1–12 months in patients 
treated with basiliximab. Patient and graft survival rates 
were not significantly different although the studies were not 
powered to detect small differences. In a pooled analysis of 
these two phase III trials, not only a significant reduction of 
acute rejection (by 44%, P  0.01) but also superior graft 
survival (96% vs 85%, P = 0.022) were evident in diabetic 
subpopulation at one-year post-transplant with comparable 
safety profile.28
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Combination of basiliximab and triple maintenance 
therapy (CsA-ME/ azathioprine/ steroids) was also evalu-
ated in a randomized multicenter study.29 During the first 
six months post-transplant, clinical acute rejection and 
BPAR occurred in 21%/19% of patients given basiliximab 
vs 35%/29% of patients administered placebo (P = 0.005). 
Basiliximab, however, did not decrease the severity of rejec-
tion or rate of steroid-resistant rejection. The incidence of 
infections including cytomegalovirus (CMV) infections and 
other side effects were indistinguishable between patients 
given basiliximab and placebo. One-year patient and graft 
survival was similar in two groups.
Vincenti and colleagues reported the first clinical trial of 
daclizumab with excellent tolerability and safety,22 which 
prompted two phase III, randomized, placebo-controlled 
clinical trials.16,17 There were a total of 535 recipients of first 
deceased donor renal transplants randomized to receive five 
doses of daclizumab or placebo. In the first study, 126 dacli-
zumab-treated recipients and 134 placebo-treated recipients 
received CsA, azathioprine, and steroids.16 The second study 
was otherwise identical (daclizumab = 116 patients, and 
placebo = 111 patients), but concurrent immunosuppression 
consisted of only CsA and steroids (dual therapy).17 In both 
studies, the addition of daclizumab significantly reduced the 
rate of BPAR (primary efficacy end-point) as compared with 
the placebo. At six months, the BPAR rate in patients treated 
with daclizumab was 22% vs 35% in those given placebo with 
triple therapy (P = 0.03),16 and 28% vs 47% with dual therapy 
(P = 0.001).17 The graft survival rates after one year tended to 
be higher in daclizumab-treated recipients in the first study 
(95% vs 90%, P = 0.08). The second study demonstrated 
better patient survival (99% vs 94%, P = 0.01), although the 
patient and graft survival of placebo patients in this study 
seemed to be lower than placebo patients in other phase III 
trials evaluating IL-2RA.17 The graft function was also better 
in daclizumab-treated patients (58 vs 51 mL/min, P = 0.02). 
Daclizumab was not associated with a higher incidence of 
infectious complications or cancers. Pooled analyses of these 
two studies demonstrated less frequent BPAR at one-year 
in daclizumab-treated patients as compared with placebo-
treated patients (28% vs 43%, P  0.01, 36% reduction by 
daclizumab).30,31 This was not accompanied by improved 
graft survival at three years (84% vs 83% for triple therapy 
and 82% vs 78% for dual therapy), while the trials were 
inadequately powered to detect differences. The pooled 
three-year patient survival rate in the dual- and triple-therapy 
trials was 93% in daclizumab- and 91% in placebo-treated 
patients (not significant [NS]). The incidence of malignancies 
or post-transplant lymphoproliferative disorder at three years 
in daclizumab and placebo patients was comparable in both 
clinical trials.
A meta-analysis of IL-2RA, including anti-Tac (murine 
IgG2a IL-2RA), BT563 (murine IgG1 IL-2RA), basilix-
imab, and daclizumab, has reported that treatment with 
IL-2RA was associated with a significant reduction in the 
risk of acute rejection at six months (odds ratio [OR] 0.51; 
95% confidence interval [CI]: 0.42 to 0.63; P  0.0001).32 
The effect on acute rejection was similar for different types 
of IL-2RA: basiliximab (OR 0.56, 95% CI: 0.44 to 0.72; 
P  0.0001) and daclizumab (OR 0.46, 95% CI: 0.32 to 0.67; 
P  0.0001). The test for heterogenicity between antibody 
groups was not significant (P = 0.7). The reduction in acute 
rejection was also similar for triple and dual immunosup-
pression regimens. There were no significant differences in 
the rate of graft loss, mortality, incidence of infections, or 
risk of malignancies at one year.
In summary, adding basiliximab or daclizumab to 
CsA-based dual or triple therapy reduces incidence of acute 
rejection without significant increase in infection or malig-
nancy, although these initial trials evaluated IL-2RAs mainly 
on low-immunological-risk patients. The effect of IL-2RA on 
graft and patient survival was not fully validated and waits 
further evaluation.
IL-2RA with MMF and/or TAC
In concert with the introduction of newer and more potent 
maintenance immunosuppressive medication, basiliximab 
and daclizumab were evaluated in different immunosuppres-
sive protocols.26,33–38 In a short report of a blind randomized 
trial, 75 patients treated with maintenance immunosuppres-
sion consisting of CsA, MMF, and steroids were administered 
daclizumab or placebo.39 There was a six-month BPAR rate 
of 12% in daclizumab-treated patients as compared with 20% 
in those receiving placebo. The combination of daclizumab 
and maintenance triple therapy with MMF was safe, well 
tolerated, and demonstrated low incidence of acute rejection. 
In another nonrandomized trial evaluating the combination 
of daclizumab with MMF/steroids/CNI (CsA-ME or TAC), 
Iverson and colleagues compared 58 patients (64% Hispanic) 
who received living donor renal allografts with a matched 
cohort of 27 patients.33 The four-month BPAR rate was 7% 
in daclizumab-treated patients vs 15% in control patients. 
There were no differences in the rate of adverse events, graft, 
and patient survival.
Lawen and colleagues randomized low-to-standard risk 
kidney transplant recipients to basiliximab (n = 59) and 
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placebo (n = 64) in addition to CsA-ME, MMF, and steroids 
in a multicenter, double-blind, placebo-controlled study.40 
Tolerability of basiliximab (the primary end point) was 
equivalent to placebo, with no increase in serious adverse 
events, infection, malignancy, or post-transplant lymphop-
roliferative disorder. At six months, while not powered to 
demonstrate a statistical significance, there were trends in 
favor of basiliximab over placebo in the incidence of first 
BPAR (15% vs 27%, P = 0.18) and of acute rejection treated 
with antibody (5% vs 16%, P = 0.08). There was also a trend 
to lower delayed graft function (DGF) and to improve graft 
function more rapidly in the basiliximab group than in the 
placebo-treated group.
A meta-analysis from the Cochrane Library included 
117 reports from 38 randomized trials utilizing IL-2RA in 
renal transplantation.41 Of those trials, 17 compared IL-2RA 
(10 basiliximab, 4 daclizumab, and 3 others) with placebo or 
no treatment, whereas 15 compared IL-2RA (9 basiliximab, 
3 daclizumab, and 3 others) with other induction therapy 
(11 polyclonal antilymphocyte/thymocyte antibodies and 
4 muromonab CD3). The majority of trials used CsA (31 CsA 
and 7 TAC) and MMF (23 MMF and 16 azathioprine). Acute 
rejection was significantly reduced at six months (relative risk 
[RR], 0.66, 95% CI: 0.59–0.74) and 12 months (RR, 0.67, 
95% CI: 0.60–0.75) when IL-2RAs were compared with 
placebo. Graft loss, death, CMV infection, malignancy, and 
DGF all favored the use of IL-2RA, but none reached sta-
tistical significance because of lack of power. When added 
to standard dual or triple therapy, IL-2RA reduced the risk 
of clinically diagnosed acute rejection by 34% and the risk 
of steroid-resistant rejection by 49% as compared with non-
induction therapy.41
TAC and MMF are often combined with more practical 
and cost-effective limited doses of daclizumab induction 
as opposed to the recommended five-dose regimen.18–20 
A multicenter study utilizing two doses of daclizumab on 
day 0 and day 10 post-transplant in 40 adult renal transplant 
recipients, in combination with TAC and MMF, demon-
strated a BPAR rate of 13% during a median follow-up 
period of 29 weeks.19 Ahsan and colleagues reported a 
prospective study comparing a single intraoperative dose 
of daclizumab (2 mg/kg, n = 50) vs noninduction (n = 50) 
in first low-immunological-risk kidney transplant patients 
treated with TAC, MMF, and prednisone.18 During the first 
six months, episodes of first BPAR were 3/50 (6%) in the 
limited daclizumab group and 8/50 (16%) in the control group 
(P  0.05). Twelve-month patient and graft survival were 
not statistically different (100% vs 98% and 100% vs 94%, 
respectively). These studies suggest that a limited dose of 
daclizumab when combined with a CNI, MMF, and steroids 
are sufficient for patients at low immunological risk to reduce 
early renal allograft rejection without adverse effects, and 
without the need for a more prolonged course of daclizumab 
as originally recommended.
iL-2rA in high-immunological-risk 
patients
While majority of patients enrolled in randomized trials 
has low-to-standard immunological risk, IL-2RAs have 
been used with MMF and either CsA or TAC to reduce 
acute rejection in high-immunological-risk patients 
(Table 1).42–45 Meier-Kriesche reported 29 black and 
20 Hispanic renal transplant recipients treated with 
daclizumab (1 mg/kg × five doses), CsA, MMF, and steroids, 
and compared with simultaneous cohort of 31 black and 
25 Hispanic patients receiving the same immunosuppression 
without daclizumab induction therapy.44 Acute rejection 
rates were lower in the daclizumab group than in the control 
group (26% vs 49% per patient years, respectively). A total 
of eight recurrent rejections in six patients occurred in the 
control group and none in the daclizumab arm. In another 
single center study, Ciancio and colleagues compared racial 
differences in incidence of BPAR among black (n = 37), 
Hispanic (n = 85), and Caucasian (n = 111) first renal trans-
plant recipients using daclizumab (1 mg/kg × five doses), 
TAC, MMF, and steroids.42 BPAR rate at one-year was 
8.1% in black, 4.7% in Hispanic, and 4.5% in the Caucasian 
group (P = 0.7). Graft and patient survival as well as renal 
function were comparable. Ciancio and colleagues also 
reported the use of daclizumab with TAC, MMF, and 
steroids in renal transplant recipients with previous trans-
plants: 4 previous liver, 15 previous kidney, and 3 previous 
pancreas/kidney.46 The incidence of  BPAR was 0%, 13%, and 
0% for previous liver, kidney, pancreas/kidney recipients, 
respectively. Few complications have occurred without CMV 
infection. These studies demonstrated the efficacy and safety 
of combining daclizumab, CNI, MMF, and steroids in high-
immunological-risk patients.
IL-2RA in CNI-sparing protocols
Because CNIs have intrinsic acute and chronic nephrotoxicity, 
IL-2RAs have been assessed for the potential addition 
to CNI-avoidance or -withdrawal after kidney transplantation 
(Table 2). The goal of this strategy is to maintain adequate 
renal function without increasing incidence of acute 
rejection.
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CNi avoidance and withdrawal
Two noncomparative studies reported complete avoidance of 
CNIs from the immunosuppressive protocol. In a multicenter 
trial reported by Vincenti and colleagues, 98 recipients of 
primary deceased or living donor kidneys at low immu-
nological risk received daclizumab (2 mg/kg for the first 
dose and 1 mg/kg for the subsequent four doses), MMF 
(3 g/day for the first six months and 2 g/day thereafter), and 
corticosteroids.47 BPAR was diagnosed in 48% of patients 
during the first six months and in 53% by 12 months after 
transplantation. At one-year post-transplant, 62% of patients 
had received CNI for more than seven days, predominantly 
because of rejection.
In a single-center study, Tran and colleagues used the 
similar protocol for 45 renal transplant recipients including 
12 black patients.48 The incidence of BPAR was 31% 
and occurred early in deceased donor transplant (median, 
7 days); 51% of the patients required the addition of CsA 
maintenance. Although theses studies provided benefits to a 
sizable minority of patients who have not required chronic 
CNI therapy with better renal function, the long-term results 
remain to be evaluated considering high incidence of acute 
rejection using this strategy.
The Cyclosporine Avoidance Eliminates Serious Adverse 
Renal-toxicity (CAESAR) trial compared CsA withdrawal 
(n = 179) and low-dose CsA (n = 183) with standard-dose 
CsA (n = 173) in low-immunological-risk recipients, all in 
combination with MMF (2 g/day) and steroids, but only with-
drawal and minimization groups received daclizumab induc-
tion (2 mg/kg before transplant followed by four more doses 
of 1 mg/kg).49 The primary end point of the study (renal func-
tion at 12 months) was not statistically different (glomerular 
filtration ratio [GFR] 51 mL/min/1.73 m2 in CsA withdrawal 
group and low-dose CsA group, and 49 mL/min/1.73 m2 in 
standard-dose CsA group). By withdrawing CsA at six months 
after transplant, the patients experienced higher incidence of 
BPAR, as compared with low-dose CsA and standard-dose 
CsA patients (38% vs 25% vs 28%, respectively, P  0.05). 
From this large-scale trial, it may be concluded that low-dose 
CsA is better than total withdrawal of CsA when combined 
with daclizumab induction, MMF, and steroids.
CNi sparing with mTOr inhibitors
IL-2RA has also been combined with long-term use 
of mammalian target of rapamycin (mTOR) inhibitors 
(sirolimus [SRL] or everolimus) in lieu of CNIs or in addition 
to low-dose CNIs. Flechner and colleagues reported five-year 
outcomes of 61 low-to-standard risk patients randomized to 
SRL (target trough level 10–12 ng/ml for six months and 
5–10 ng/ml thereafter) or CsA (target trough level 200 ng/ml 
for one year and 150–170 ng/ml thereafter) after basiliximab 
induction and MMF with steroids.50,51 SRL-treated patients 
compared with CsA-treated patients demonstrated similar 
patient survival (87% vs 90%) and acute rejection rates 
(13% vs 23%), respectively. In SRL-treated patients, 
death-censored graft survival rate was higher (96% vs 
77%, P = 0.027) and GFR was higher (67 vs 51 mL/min, 
P = 0.008) with similar urine protein and serum choles-
terol levels. Martinez-Mier and colleagues used a similar 
protocol for 41 living related kidney transplants in a single 
center randomized trial, showing comparable patient and 
graft survival.52 Although the rejection rate was numerically 
high in SRL-treated patients (17% vs 5%, NS), none of the 
patients who had target SRL levels suffered acute rejection 
at one year.
The Efficacy Limiting Toxicity Elimination (ELITE)-
Symphony study is a prospective, randomized, open-label, 
multicenter trial comparing four parallel groups of adult 
renal transplant recipients.53 Low-immunological-risk 
patients were randomly assigned to standard-dose CsA 
Table 1 immunological risk status
Population risk status Race Transplant type PRA HLA mismatch Donor type CIT DGF
Low Caucasian Primary PrA  10% 0 Living related donor 18 hours No
Standard
High Black repeat PrA  80% 6 expanded criteria 36 Yes
transplant with donor hours
immunological Donor after cardiac
loss of a death
previous allograft (Deceased donor)
Notes: Patients are often categorized as “low risk” or “high risk” when some of the above criteria are met; “standard risk” are in between “high risk” and “low risk”, but 
actual definition may vary in each study.
Abbreviations: CiT, cold ischemia time; DGF, delayed graft function; HLA, human leukocyte antigen; PrA: panel reactive antibody.
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(n = 390, target trough level, 150–300 ng/ml for three months 
and 100–200 ng/ml thereafter), low-dose CsA (n = 399, tar-
get trough level, 50–100 ng/ml), low-dose TAC (n = 401, 
target trough level, 3–7 ng/ml), or low-dose SRL (n = 399, 
target trough level, 4–8 ng/ml). All groups received MMF 
(2 g/day) and corticosteroids. Daclizumab (2 mg/kg before 
transplant followed by four more doses of 1 mg/kg) was given 
to all but the standard-dose CsA group. Estimated GFR at 
one year (the primary end point) was significantly higher in 
the low-dose TAC group (65 mL/min) than in the other three 
groups (57–59 mL/min, P  0.001). BPAR rate at one year 
was lower in the low-dose TAC group (12.3%) than in the 
other three groups (standard-dose CsA 25.8%, low-dose CsA 
24.0%, low-dose SRL 37.2%; P  0.001). Death-censored 
allograft survival was higher in the low-dose TAC group 
(96%) than in the standard-dose CsA and the low-dose SRL 
groups (both 92%; P = 0.007). Serious adverse events were 
observed in 53% of patients in the low-dose SRL group, as 
compared with 43%–44% in the other groups (P  0.05). 
Based on the results above, when daclizumab is combined 
with low-dose TAC, outcomes seem to be better than standard 
CsA-MMF-steroid-based regimen without induction therapy; 
however, when daclizumab is combined with low-dose SRL 
without CNIs, outcomes seem to be worse than the standard 
triple regimen.
Low-dose CNI with mTOR inhibitor has been tested in 
other studies. Nashan and colleagues compared full-dose 
CsA (n = 53, trough level, 125–250 ng/ml) and reduced-dose 
CsA (n = 58, trough level, 50–100 ng/ml) in combination 
with basiliximab, everolimus (3 mg/day) and steroids in a 
randomized, multicenter, open-label study (156 study) of 
low-to-standard risk patients.54 In the reduced-dose CsA 
group, a lower incidence of BPAR (3% vs 15% at six months 
and 7% vs 17% at one year) was accompanied by higher 
mean creatinine clearance (61 vs 54 mL/min at one year, 
P  0.007) and less frequent discontinuations and serious 
adverse events. Vitko and colleagues and Tedesco-Silva and 
colleagues reported six- and 12-months safety and efficacy 
results of two randomized studies (A2306 and A2307) of 
low-to-standard risk patients using the similar immunosup-
pressive medication.55,56 Study 1 (A2306, n = 237) had no 
induction therapy; in Study 2 (A2307, n = 256) basiliximab 
was administered. These studies compared two different 
doses of everolimus (1.5 vs 3 mg/day) with steroids and 
reduced-dose CsA (initial CsA C
2
 target 1200 ng/ml for 
Study 1 and 600 ng/ml for Study 2 with subsequent tapering 
to 400 ng/ml for both studies). As black patients have a higher 
everolimus clearance rate than Caucasian patients, all black vi
nc
en
ti 
et
 a
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subjects received 3 mg/day everolimus. These regimens 
were well tolerated and preserved renal function throughout 
the study, with no differences observed between groups 
within studies. Without basiliximab induction, there was a 
trend towards a reduction in the incidence of BPAR among 
nonblack randomized to 3 mg/day everolimus as compared 
with 1.5 mg/day everolimus (16% and 26% at 12 months, 
respectively; P = 0.08). The inclusion of basiliximab 
lowered the overall incidence of acute rejection (15% for 
3 mg/dl and 14% for 1.5 mg/dl at six months; 16% vs 14% 
at 12 months).
Delayed CNi introduction
As designed in phase I/II studies, the other potential use 
of IL-2RA induction is to delay introduction of CNIs to 
prevent acute nephrotoxicity while the transplanted kidney 
has delayed or slow graft function.13 Small studies reported 
initial CNI avoidance with a combination of daclizumab/
basiliximab, SRL, and steroids. This regimen provided 
reasonable acute rejection prophylaxis in 43 kidney recipi-
ents (acute rejection rate 16%).57 In a retrospective analysis 
of 14 patients, Chang and colleagues added MMF to this 
regimen, resulting in an acute rejection rate of 14% and 
graft survival rate of 100% during the follow-up period 
of 0.5–5.2 months.37 Although SRL may prolong recovery 
from DGF,58 the ability of IL-2RA to protect kidneys from 
acute rejection with excellent safety profile makes this 
strategy attractive. Moreover, it has been suggested that use 
of an IL-2RA may decrease the risk of delayed or slow graft 
function.12,59,60
The French Myeariade FR01 study group evaluated early 
and delayed CsA in a 12-month, prospective, randomized, 
open-label study of de novo low-risk renal transplant 
patients.61,62 CsA-ME at an initial dose of 8 mg/kg/dose 
was started either on day 0 (n = 97) or day 6 (n = 100) 
post-transplant, and dose adjusted according to C
2
 level. 
All patients received enteric-coated mycophenolate sodium, 
steroids, and either two doses of basiliximab or five doses 
of daclizumab. One-third of patients in both groups had a 
DGF Risk Index Score of 5 (US Renal Data System). 
The incidence of BPAR was numerically high (26% vs 
16%; P = 0.11) at 12 months in the delayed CsA-ME group 
as compared with the early CsA-ME group, although the 
study was not powered to detect differences. Early or 
delayed introduction of CsA-ME did not affect renal function 
(51 ml/min vs 54 ml/min at three months; P = 0.43) or DGF 
rate (27% vs 23%; NS). The extension of this study with 
a mean follow up of 30 months demonstrated comparable 
creatinine clearance between groups. NI2A Study Group 
in Spain also compared different patterns of CsA initiation 
in renal transplant recipient from expanded criteria donors 
and high risk of DGF: early low-dose CsA (3 mg/kg/day, 
n = 38), early standard-dose CsA (5 mg/kg/day, n = 40), 
and delayed standard-dose CsA (5 mg/kg/day 7–10 days 
after transplant, n = 36).63 This multicenter six-month, 
open-label, randomized trial with basiliximab, MMF, and 
steroids revealed no differences among groups in six months 
GFR, DGF rate (31%, 38%, and 42% for early low-dose 
CsA, early standard-dose CsA, delayed standard-dose CsA, 
respectively), and BPAR rate (5%, 13%, and 11%), although 
combined clinically treated and BPAR rate was significantly 
higher in the delayed CsA group (5%, 15%, and 25%). These 
results suggest delayed introduction of CNIs with IL-2RA, 
MMF, and steroids does not improve renal function or lower 
DGF rate; it may increase acute rejection episodes.
In summary, results of CNI sparing protocols have 
been mixed. Minimization of CNIs may be associated 
with improved renal function; however, CNI avoidance or 
withdrawal often increases risk of acute rejection. Further 
study is needed to determine whether the short-term 
benefit of CNI minimization translates into long-term 
improvement of graft and patient survival with alternative 
immunosuppressive medication including IL-2RA induction 
and mTOR inhibitors.
IL-2RA in corticosteroid 
sparing protocols
Corticosteroids have been a mainstay of immunosuppression 
for several decades despite their major adverse effects: 
hypertension, diabetes, dyslipidemia, bone loss, avascular 
necrosis, weight gain, cataracts, and psychotic behavior. 
Although these side effects may increase mortality and 
morbidity after transplantation, steroid withdrawal has been 
associated with high rejection rate and poor graft survival.64–67 
To prevent rejection early post-transplant, antibody induction 
including IL-2RA has been utilized in steroid-sparing 
protocols (Table 3).
Steroid withdrawal with CNis and MMF
A pilot study by Cole and colleagues introduced daclizumab 
and MMF to a CsA-based immunosuppressive protocol to 
avoid steroid use. Sixty-five percent of patients remained 
steroid-free with acute rejection rate of 25%, suggesting 
this as a practical strategy.68 Vincenti and colleagues 
randomized 84 low-to-standard risk primary renal transplant 
recipients receiving basiliximab, CsA-ME, and MMF to 
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either corticosteroid withdrawal at day 4 post-transplant 
or standard steroid therapy.69 The incidence of BPAR at 
12 months was comparable (20% vs 16%; P = 0.73) with 
100% death-censored graft survival in both groups. The 
majority (72%) of patients remained off steroids, showing 
feasibility of steroid-withdrawal with basiliximab.
With TAC and MMF-based immuosuppression, ter 
Meulen and colleagues randomized low-to-high risk patients 
to three-day steroids plus two doses of daclizumab (dacli-
zumab group, n = 186) and four-month steroids (control 
group, n = 178).21 The incidence of BPAR at 12 months (15% 
vs 14%) and graft survival (91% vs 90%) were comparable 
between the daclizumab and control groups. Mean arterial 
blood pressure, serum lipids, and incidence of patients with 
hyperglycemia were temporarily lower in the daclizumab 
group than controls. The efficacy of daclizumab was also 
tested in the CARMEN study: an open-label, multicenter, 
parallel-group study with 538 low-to-standard risk renal 
patients randomized to a daclizumab/TAC/MMF or a 
TAC/MMF/corticosteroids.70 The patients who received 
two doses of daclizumab and no steroids demonstrated the 
same low BPAR rate (17% in both groups) as compared 
with controls. The steroid-free patients were found to have 
reduced incidence of insulin-dependent new-onset diabetes 
after transplantation (0.4% vs 5.4%; P = 0.003), lower total 
cholesterol level, and similar renal function. These results 
suggest daclizumab is as effective at preventing acute rejec-
tion after renal transplantation as a standard triple regimen 
and its safety benefits may help improve the long-term out-
come of renal transplant patients.
Parrott and colleagues tested the effectiveness of 
basiliximab in avoiding addition of steroids to CsA-ME 
monotherapy.60 In the low-to-standard immunological 
risk patients randomized to receive basiliximab (n = 52) 
or placebo (n = 56), more placebo-treated patients (73%) 
required additional immunosuppression at 12 months 
than basiliximab-treated patients (54%, P = 0.05). BPAR 
episodes were observed more frequently in placebo (43%) 
than in basiliximab (29%) although it was not statistically 
significant (P = 0.16). These findings suggest the efficacy 
of basiliximab as compared with placebo in steroid-sparing 
regiments. However, in the Atlas Study, Vitko and colleagues 
reported higher incidence of BPAR in steroid-free patients at 
low-to-standard immunological risk.71 Two steroid-free regi-
ments (TAC monotherapy after basiliximab induction and 
TAC/MMF) had BPAR rate of 26% and 31%, respectively, as 
compared with standard triple therapy (TAC/MMF/steroids) 
of 8% (P  0.001). Graft and patient survival were similar 
in all groups as was the renal function at six months. The 
basiliximab/TAC therapy offered some safety benefits (fewer 
events of leucopenia, diarrhea, and CMV infection).
Woodle and colleagues for the Astellas Corticosteroid 
Withdrawal Study Group recently published five-year 
results of a prospective, randomized, double-blind, 
placebo-controlled multicenter trial comparing seven-day 
corticosteroid cessation versus long-term, low-dose corti-
costeroid therapy.72 About one-third of the patients at low 
risk in each group received either basiliximab or daclizmab, 
while two-thirds of patients received antithymocyte 
globulin. Overall, there was no difference in a composite 
outcome of death, graft loss, or moderate/severe acute 
rejection (16% and 14% in steroid withdrawal group and 
chronic steroid group, respectively). The BPAR rate at 
five years was numerically higher (18% vs 11%; P = 0.06) 
and the Kaplan–Meier analysis of BPAR was significantly 
higher in the steroid withdrawal group (P = 0.04) primarily 
because of mild, Banff 1A, steroid-sensitive rejection. Of 
note, subgroup analysis revealed similarly low incidence 
of BPAR with chronic steroid use in patients induced with 
antithymocyte globulin (10%) and IL-2RA (12%); the 
incidence of BPAR was numerically higher with IL-2RA 
(24%) than antithymocyte globulin (14%, P = 0.09) in 
steroid-withdrawal patients. Corticosteroid withdrawal was 
associated with improved serum triglycerides, less body 
weight change, and fewer insulin-dependent new-onset 
diabetes after transplant.
Another recently published trial using basiliximab is 
the FREEDOM study, which compared complete steroid 
avoidance and seven-day steroid withdrawal with stan-
dard chronic steroid therapy.73 Vincenti and colleagues 
randomized 336 low-risk renal patients into three treatment 
groups with CsA-ME, enteric-coated mycophenolate sodium, 
and basiliximab. The 12-month incidence of BPAR, graft 
loss, or death of the intent-to-treat population was 36% in 
the steroid-free group (P  0.01 vs standard), 30% in steroid 
withdrawal (NS vs standard) and 19% in standard steroids. 
BPAR was significantly more frequent with steroid free 
and steroid withdrawal than standard steroids (steroid free 
32%, P  0.01; steroid withdrawal 26%, P = 0.05; standard 
steroids 15%). GFR at 12 months was similar and investi-
gational groups were not inferior to standard steroids in the 
observed-case analysis. Favorable outcomes in new-onset 
diabetes after transplant, dyslipidemia, and weight gain were 
observed in one or both steroid-minimization groups versus 
standard steroids. These results suggest steroid withdrawal 
at one week is more desirable than steroid avoidance 
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for standard-risk renal recipients receiving basiliximab, 
CsA-ME, and enteric-coated mycophenolate sodium.
Pascual and colleagues recently published meta-analysis 
of steroid avoidance or withdrawal for kidney transplant 
recipients in the Cochrane Library.74 Overall, acute rejection 
was more frequent with a steroid-sparing strategy analyzing 
intent-to-treat population (RR 1.27, 95% CI: 1.14–1.40), or 
only biopsy-proven cases (RR 1.59, 95% CI: 1.21–2.11), 
although none of the steroid withdrawal (2 weeks post-
transplant) studies and only about a half of the steroid 
avoidance (2 weeks post-transplant) studies analyzed 
were induced by IL-2RA. Steroid withdrawal showed no 
effect on death, graft loss, or acute rejection; whereas steroid 
avoidance showed no effect on death or graft loss, but more 
frequent acute rejection as compared with steroid use and 
maintenance. In a subgroup analysis stratified by the type 
of CNI (CsA and TAC), higher incidence of acute rejection 
was only evident in studies using CsA. A meta-analysis 
comparing with or without induction, or comparing the type 
of induction was not performed.
Steroid withdrawal with CNis  
and mTOr inhibitors
IL-2RA induction has been used with mTOR inhibitor-based 
immunosuppression to minimize steroid use. Woodle and 
colleagues combined basiliximab, TAC, and SRL in a single 
arm multicenter pilot study.75 Low-risk renal recipients were 
withdrawn from steroids four days after transplantation and 
demonstrated excellent one-year patient and graft survival 
(both 100%). BPAR occurred in 13% and presumptive 
rejection 11%, with good renal function and safety profile. 
Anil Kumar and colleagues compared SRL and MMF (n = 
75 each) in combination with basiliximab, TAC, and two-
day steroid (60% black recipients) with surveillance biopsy 
at 1, 6, 12, and 24 months post-transplant.76 BPAR was 
seen in 12% of TAC/MMF and 8% of TAC/SRL patients. 
Surveillance biopsy showed that cumulative incidence of 
subclinical acute rejection was 27% in TAC/MMF and 
16% in TAC/SRL groups at two years (P = 0.04), and that 
moderate/severe chronic allograft nephropathy was 22% 
and 10%, respectively (P = 0.06). Two-year patient and 
graft survival were equivalent. A comparison of steroid 
withdrawal and standard steroids of the same investigators 
showed no increase in BPAR, subclinical acute rejection, or 
chronic allograft nephropathy; and low incidence of new-
onset diabetes after transplant (4% vs 21%, P  0.01) in 
the steroid withdrawal group.77 In contrast to above studies, 
Gallon and colleagues reported a single-center analysis of G
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low-to-standard risk renal recipients comparing TAC/MMF 
(n = 45) and TAC/SRL (n = 37) with basiliximab plus 
two-day steroids.78 During the three-year follow-up, graft 
survival was significantly better in TAC/MMF group (98%) 
than in TAC/SRL group (84%, P = 0.04). Numerically fewer 
patients experienced BPAR in TAC/MMF (8/45, 18% vs 
11/37, 30%, P = 0.31). Of note, 70% of the rejection occurred 
within 30 days post-transplant in both group, suggesting 
inadequate initial protection by basiliximab.
Utilizing another mTOR inhibitor, Montagnino and 
colleagues randomized 133 de novo renal transplant recipients 
at low-to-standard risk to seven-day steroid withdrawal 
and low-dose chronic steroids with basiliximab, low-dose 
CsA-ME, and everolimus.79 There were more BPAR in ste-
roids withdrawal group (21/65, 32%) than in the low-dose 
steroid group (12/68, 18%, P = 0.06). Graft survival was 
paradoxically high in steroid withdrawal group (95% vs 87%, 
NS) but only 54% of the patients were steroid-free at three 
years after transplant: 17 resumed steroids because of acute 
rejection and 13 were never withdrawn from steroids because 
of slow graft function. Larger randomized studies are needed 
to confirm these results and clarify the benefits of steroid with-
drawal in CsA-mTOR inhibitor-based immunosuppression.
Steroid withdrawal  
in high-immunological-risk patients
In high-immunological-risk patients, Alloway and colleagues 
withdrew steroids from TAC (target trough level, 4–8 ng/ml), 
SRL (target trough level, 8–12 ng/ml), and MMF (2 g/day).80 
Although initial 10 patients received daclizumab induction 
(2 mg/kg on days 0 and 14), the protocol for the next 
15 patients was modified, because of high acute rejection 
rate, to receive antithymocyte globulin (1.5 mg/kg on days 
0 and 2) followed by daclizumab on day 14. Of 25 patients, 
40% were black, 68% repeated transplant, and 36% had peak 
flow PRA  25%. The incidence of acute rejection was 60% 
with daclizumab and 27% with antithymocyte globulin plus 
daclizumab. Anil Kumar and colleagues evaluated the safety 
and efficacy of steroid withdrawal at day 2 post-transplant in 
black (n = 103) as compared with nonblack (n = 103) kidney 
recipients.81 Induction was basiliximab and maintenance 
was CNI (TAC target trough level, 15–18 ng/ml or CsA 
target C2 level, 1000–1200 ng/ml) plus MMF (2 g/day) or 
SRL (target trough level, 5–10 ng/ml). Although BPAR 
rates at one-year were similar (16% for black and 13% for 
nonblack), the incidence of subclinical acute rejection at 
one month was higher in the black group than the nonblack 
group (23% vs 11%; P = 0.04). A five-year follow-up of 
the study demonstrated still a significant difference of 
subclinical acute rejection but no difference in clinical 
BPAR (16% vs 14%, P = 1.0).82 Five-year patient surviv-
als were 81% and 88% (P = 0.09) and graft survivals were 
71% and 73% (P = 0.19) in the black and nonblack groups, 
respectively. Prevalence of chronic allograft injury (48% vs 
30%; P = 0.05), interstitial fibrosis/tubular atrophy (47% 
vs 32%; P = 0.05), and mean serum creatinine levels (2.1 vs 
1.8 mg/dl; P = 0.05) were all higher in the black group.
In summary, early steroid withdrawal in low-to-standard 
immunological risk patients with IL-2RA induction and 
CNI-based maintenance therapy is possible with minimal 
increasing risk of rejection and is probably better than 
total avoidance of steroids. Steroid-sparing may decrease 
incidence and severity of steroid-related adverse events; 
however, long-term benefits of this strategy have not yet 
been proven.
Comparison of IL-2RA  
and other antibodies
Basiliximab vs daclizumab
No large-scale randomized study has directly compared 
two different IL-2RAs. Nair and colleagues reported a 
small open-labeled prospective study of 23 renal transplant 
recipients comparing the efficacy of basiliximab (20 mg on 
day 0 and day 4) and daclizumab (1 mg/kg for five doses) 
with baseline immunosuppression of CsA, MMF, and 
steroids.83 There was no significant difference in the rate of 
acute rejection, 10% with basiliximab and 8% with dacli-
zumab; time to first rejection episode was eight days with 
basiliximab versus six weeks with daclizumab. There was 
no difference in patient and graft survival (100%) between 
the two groups at 10 months follow-up. Lin and colleagues 
randomized 30 patients to basiliximab and 28 patients to 
daclizumab with CsA, reduced-dose MMF (1 g/day), and 
steroids.84 At six months, the incidence of BPAR was 0% with 
basiliximab and 21% with daclizumab (P  0.05). However, 
relatively low-dose daclizumab (fixed dose of 50 mg on 
days 0 and 14) was used in this study as compared with other 
two-dose regimen studies using total dose of 4 mg/kg.85,86 
Two meta-analyses of randomized trials utilizing IL-2RA in 
kidney transplantation demonstrated a similar effect on acute 
rejection for basiliximab and daclizumab: OR 0.56 vs 0.46 in 
the first study and RR 0.67 vs 0.66 in the second study.32,41
iL-2rA vs muromonab CD3
Ciancio and colleagues retrospectively compared first kidney 
transplant patients with daclizumab induction (n = 233) and 
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muromonab CD3 (OKT3) induction (n = 225).87 Daclizumab 
was administered in standard five doses (1 mg/kg every other 
week) and muromonab CD3 7–14 doses (5 mg daily) with 
delayed (2–3 days) TAC, MMF, and steroids. At six months, 
the BPAR rate was significantly lower in daclizumab-treated 
patients (2%) than in muromonab CD3-treated patients 
(7%, P = 0.01). One-year patient and graft survival for 
the daclizumab group was 98% and 96% vs 96% and 94% 
for the muromonab CD3 group, respectively (NS). The 
incidence of infection requiring hospitalization was lower 
with daclizumab (7 vs 16%; P  0.004) with a similar trend 
with CMV infection (2% vs 4%; P = 0.14). In an updated 
report of additional recipients (n = 305), the efficacy and 
safety of daclizumab was still observed: BPAR rate of 5% 
with median follow-up of 27 months and CMV infection in 
1.6% of the patients.88 The median length of hospital stay 
was shorter in the basiliximab group than the muromonab 
CD3 group (10 vs 13 days; P = 0.0001). A similar observa-
tion was reported by Kode and colleagues.89 In a single-center 
study, 100 standard-to-high immunological risk patients 
who received a first or second kidney graft from deceased 
donor were treated with two doses of basiliximab, low-dose 
CsA, MMF, and reduced-dose steroids. A historical control 
group consisted of 26 patients who received muromonab 
CD3 (7–14 daily doses), delayed full-dose CsA, MMF, and 
high-dose steroids. Despite a 40% reduction in steroids, 
basiliximab-treated patients had fewer BPAR (basiliximab 
14% vs muromonab CD3 35%) and required less antilympho-
cyte antibody therapy. Length-of-stay, number of readmis-
sions, total hospitalization days, and CMV infections were 
lower in the basiliximab group.
iL-2rA vs antithymocyte globulin
Sollinger and colleagues compared the safety and efficacy 
of basiliximab (n = 70) and equine antithymocyte globu-
lin (ATGAM; n = 65) with CsA-ME, MMF, and steroids 
in low-to-standard risk patients.90 At 12 months, the rate 
of BPAR was 19% and 20%, respectively, in the basilix-
imab and antithymocyte globulin groups; graft survival, 
patient survival, and adverse event profile were similar. 
Lebranchu and colleagues compared basiliximab plus early 
CsA-ME (n = 50) versus rabbit antithymocyte globulin 
(Thymoglobulin®) plus delayed CsA-ME (n = 50) in low-risk, 
first, deceased-donor kidney transplant patients; all patients 
received MMF and steroids.91 The incidences of BPAR (8% 
in each group) and treatment failure (14% in the basiliximab 
group vs 8% in the antithymocyte globulin group) were 
comparable in the two groups. There was a tendency to more 
DGF requiring dialysis (14% vs 6%) and significantly fewer 
CMV infections (12% vs 38%; P = 0.005) in the basiliximab 
group. Another small comparison of low-risk renal patients 
receiving daclizumab (n = 10) and antithymocyte globulin 
(Fresenius, n = 35) indicated comparable efficacy and fewer 
infectious complications in the daclizumab group.92 Kyllonen 
and colleagues reported five-year results of a single-center 
study randomizing standard-risk patients to single bolus 
antithymocyte globulin (Fresenius, 9 mg/kg over 30 min 
before reperfusion), basiliximab (20 mg before reperfusion 
and on day 4), and no induction.93 All patients received 
CsA, azathioprine, and steroids, but CsA blood trough level 
was significantly high in no induction group during the first 
week post-transplant. BPAR rate was numerically low in 
two induction groups compared with no induction group 
(antithymocyte globulin 11%, basiliximab 12%, and no 
induction 21%, NS). Antithymocyte globulin was associ-
ated with lower incidence of DGF (6%, 24%, and 16%; 
P  0.03) and higher incidence of adverse events during 
infusion (ie, low blood pressure, high airway pressure, and 
low oxygen saturation). Patient and graft survival was similar 
at five years except that basiliximab group had higher graft 
survival than no induction group (97% vs 84%; P  0.05). 
In terms of long-term adverse events including CMV infec-
tion, there were no statistically significant differences among 
the three groups.
Two recent open-label, multicenter, randomized studies 
compared basiliximab and rabbit antithymocyte globulin 
(Thymoglobulin®). Mourad and colleagues randomized 
105 low-risk renal transplant patients to basiliximab and 
antithymocyte globulin with delayed CsA-ME, MMF, and 
steroids.94 The incidence of BPAR was comparable (basilix-
imab 10% vs antithymocyte globulin 9%) as were the graft 
survival (94% vs 96%), patient survival (98% for both studies), 
DGF rate (29% vs 30%), and renal function (mean serum 
creatinine nadir 163 vs 156 µmol/L). However, significantly 
fewer patients in the basiliximab group experienced CMV 
infection, leukopenia, and thrombocytopenia, and this was 
without any significant difference in any other key safety 
parameters (including the incidence of serum sickness, fever, 
lymphoma, and infections in general). Brennan and colleagues 
reported an international study comparing a short course of 
antithymocyte globulin (Thymoglobulin® 1.5 mg/kg intraop-
eratively and four more daily doses, n = 141) and basiliximab 
(20 mg on days 0 and 4, n = 137) in patients at high risk 
for acute rejection or DGF who received a deceased-donor 
renal transplantation.95,96 Both groups received CsA-ME, 
MMF, and steroids for maintenance immunosuppression. 
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The antithymocyte globulin group, as compared with the 
basiliximab group, had lower incidences of BPAR (16% vs 
26%, P = 0.02 at one year) and antibody-treated BPAR (1.4% 
vs 8%; P = 0.005 at one year). The antithymocyte globulin 
group and basiliximab group had similar incidence of DGF 
(40% vs 45%), graft survival (91% vs 90% at one year, 69% 
vs 63% at five years) and patient survival (96% vs 96% at one 
year, 76% vs 80% at five years). The incidence of all adverse 
events, serious adverse events, and cancers were also similar 
between the two groups at one year. The patients receiving 
basiliximab had a lower incidence of infection (86% vs 75%; 
P = 0.03 at one year); contrary to other studies, the incidence 
of CMV disease was higher in the basiliximab group (8% 
vs 18%; P = 0.02 at one year). These findings suggest that 
incidence of acute rejection is comparable with IL-2RA 
and antithymocyte globulin in kidney transplant recipients 
at low-immunological- risk, but the risk of rejection may be 
higher with IL-2RA in patients at high risk.
iL-2rA vs alemtuzumab
Kaufman and colleagues reported a nonrandomized, retro-
spective sequential study comparing outcomes in kidney 
transplant recipients induced with either alemtuzumab 
(n = 123) or basiliximab (n = 155) in combination with a 
steroid-free maintenance protocol using TAC and MMF.97 
The one-year actual death-censored graft survival rates for 
recipients who received alemtuzumab and basiliximab were 
both 99%; the one-year actual patient survival rates were 97% 
vs 99% (NS). A lower rate of early (3 months) rejection was 
observed in the alemtuzumab versus the basiliximab group 
(4% vs 12%, respectively), but the rates for both groups were 
equivalent at one year (15% and 14%). At one year, serum 
creatinine concentration was similar (1.42 ± 0.59 mg/ml 
for the alemtuzumab group and 1.36 ± 0.48 mg/ml for the 
basiliximab group). The incidence and etiology of infectious 
disease were very similar: CMV infection occurred in 4% and 
5% of the recipients in the alemtuzumab and basiliximab 
groups, respectively. The incidence of CMV in CMV-naïve 
recipients who received CMV-positive donor organ were 21% 
and 19% in the respective two groups. Authors concluded 
that alemtuzumab induction therapy was similar in efficacy 
to basiliximab in a steroid-free maintenance immunosuppres-
sive protocol for kidney transplant recipients.
At our institution, Ciancio and colleagues randomized 90 
first deceased-donor renal transplant recipients (50% non-
Caucasian) into three different antibody induction agents: 
group A received rabbit antithymocyte globulin, group B 
alemtuzumab, and group C daclizumab.98,99 Maintenance 
immunosuppression included TAC and MMF in all three 
arms, and corticosteroids in groups A and C only. The 
targeted trough TAC level was 8–10 ng/ml for groups A 
and C, with a targeted MMF dose of 1 g twice daily. In 
group B, target trough TAC level was 4–7 ng/ml (to reduce 
long-term nephrotoxicity), with 500 mg twice-daily doses of 
MMF and without corticosteroid maintenance. In a 15-month 
median postoperative interval report, there were no notable 
differences in demographics or patient and graft survival.98 
However, a following report with a minimum follow-up 
of 27 months showed significantly poorer death-censored 
graft survival in group B as compared with group A and 
C combined (P = 0.01).99 BPAR rates at one year were 
equivalent, ie, 5 of 30 in all three groups (17%). Longer 
follow-up again showed equivalent BPAR rate, but higher 
incidence of chronic allograft nephropathy in group B (37%, 
P = 0.008) as compared with group A (17%) and group C 
(10%). In group B, there was slightly lower renal function 
throughout the observation. There was also significantly 
more leukopenia, but a greater percentage of T regulatory 
cells and number of Fox-P3 mRNA copies in group B. 
There were no differences in other adverse events. These 
results indicate that with the alemtuzumab induction, 80% 
of patients remain steroid-free two years postoperatively; 
however, they have higher incidence of immunological 
graft loss, chronic allograft nephropathy, and poor renal 
function. IL-2RA induction with conventional maintenance 
immunosuppression may be superior to alemtuzumab induc-
tion with low maintenance in a certain patient population.
Combination of iL-2rA  
and other antibodies
Vincenti and colleagues randomized mainly low-risk patients 
receiving deceased or living donor kidney graft into three 
immunosuppressive regimens to test the efficacy of belata-
cept (selective costimulation blocker, binds CD80 and CD86 
of antigen-presenting cells) without CNI maintenance.100 
Patients in the intensive belatacept group received belatacept 
10 mg/kg × 11 doses in the first six months with subsequent 
5 mg/kg doses every 4–8 weeks; patients in the less-intensive 
belatacept group received belatacept 10 mg/kg x five doses in 
the first three months with subsequent 5 mg/kg doses every 
4–8 weeks; and patients in the CsA group received CsA 
maintenance. All patients received induction therapy with 
20 mg of basiliximab on days 0 and 4, 2 g of MMF daily, 
and a corticosteroid-tapering regimen to 5 mg per day. At 
six months, the incidence of BPAR was similar among the 
groups: 7% for intensive belatacept, 6% for less-intensive 
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belatacept, and 8% for CsA. At 12 months, the measured 
GFR was significantly higher among patients receiving 
the intensive and less-intensive belatacept regimens than 
among those receiving CsA (66, 62, and 54 ml/min/1.73 m2, 
respectively; P  0.05). Chronic allograft nephropathy was 
less common with both regimens of belatacept than with CsA 
(29%, 20%, and 44%, respectively). Overall, adverse event 
profiles are in favor of both belatacept regimens, suggesting 
potential long-term benefit of less toxic antibody therapy with 
IL-2RA and costimulation blockade.
Finally, Ciancio and colleagues combined truncated 
daclizumab (1 mg/kg × 2 doses on days 0 and 14) and short-
course of rabbit antithymocyte globulin (1 mg/kg × three 
doses on days 0, 3, and 5) along with reduced-dose TAC, 
early steroid withdrawal (one week), and either MMF or 
enteric-coated mycophenolate sodium for 150 first kidney 
transplant recipients consisting of 36% Caucasian, 30% 
Hispanic, and 29% black.101 At 12 months, overall incidence 
of BPAR was 6% and BPAR requiring antibody treatment 
was 3%. One-year patient and graft survival was 99% and 
96%, respectively. The percentage and types of infectious 
complications requiring hospitalization during the first 
12 months post-transplant was acceptably low (14% for 
all infection, 0.7% for CMV infection). The incidence of 
new-onset diabetes mellitus after transplantation was 11%; 
gastrointestinal side effects were seen in 16% of the patients 
without significant difference by maintenance immunosup-
pressive regimen. This study demonstrates the efficacy 
and safety of combined induction therapy with IL-2R and 
lymphocyte-depleting antibody with low-dose CNI and rapid 
steroids elimination for an ethnically diverse population of 
renal transplant recipients.
Conclusions
The use of antibody induction after kidney transplantation 
has increased from 25% to 63% in the past decade and 
roughly one half of the induction agent used is IL-2RA, ie, 
basiliximab or daclizumab.102
Evidence supports basiliximab and daclizumab, as 
compared with placebo, equally reduce incidence of acute 
rejection without significant increase in incidence and severity 
of adverse events. In many immunosuppressive combinations, 
efficacy of IL-2RA for low- and standard-immunological-risk 
patients is similar to that of lymphocyte-depleting antibodies 
and the safety profile is usually better than other antibody 
preparations.
Given the high safety and tolerability profile, IL-2RAs 
have successfully been used with steroid- and CNI-sparing 
protocols in order to reduce toxicities of immunosuppressive 
medications. For low-to-standard risk patients, early steroid 
withdrawal with IL-2RA seems to be feasible with mini-
mal, if at all, increasing risk of rejection when combined 
with CNI-based immunosuppressive regimens. In contrast, 
results of CNI-sparing protocols with IL-2RA have been 
mixed. CNI withdrawal may be associated with improved 
renal graft function and minority of patients may benefit 
from this strategy, CNI minimization, however, often 
increases risk of acute rejection. Further studies are needed 
to evaluate the overall benefits of these new strategies on 
the long-term survival of patients and allografts.
Disclosures
The authors have no conflicts of interest that are directly 
relevant to the content of this review.
References
 1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, 
Stablein D. Improved graft survival after renal transplantation in the 
United States, 1988 to 1996. N Engl J Med. 2000;342(9):605–612.
 2. Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an 
acute rejection episode on long-term renal allograft survival (t1/2). 
Transplantation. 1994;57(6):857–859.
 3. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejec-
tion in renal allograft recipients. Transplantation. 1993;55(4):752–756; 
discussion 756–757.
 4. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Chapman JR, 
Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment 
by protocol histology. Transplantation. 2004;78(4):557–565.
 5. Citterio F. Steroid side effects and their impact on transplantation 
outcome. Transplantation. 2001;72(12 Suppl):S75–S80.
 6. Jamil B, Nicholls K, Becker GJ, Walker RG. Impact of acute rejection 
therapy on infections and malignancies in renal transplant recipients. 
Transplantation. 1999;68(10):1597–1603.
 7. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospec-
tive trial of anti-Tac monoclonal antibody in human renal transplanta-
tion. Transplantation. 1991;51(1):107–113.
 8. Reed MH, Shapiro ME, Strom TB, et al. Prolongation of primate renal 
allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal 
antibody. Transplantation. 1989;47(1):55–59.
 9. Tighe H, Friend PJ, Collier SJ, et al. Delayed allograft rejection 
in primates treated with anti-IL-2 receptor monoclonal antibody 
Campath-6. Transplantation. 1988;45(1):226–228.
10. van Gelder T, Zietse R, Mulder AH, et al. A double-blind, placebo-
controlled study of monoclonal anti-interleukin-2 receptor antibody 
(BT563) administration to prevent acute rejection after kidney trans-
plantation. Transplantation. 1995;60(3):248–252.
11. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, 
Soulillou JP. Randomised trial of basiliximab versus placebo for 
control of acute cellular rejection in renal allograft recipients. CHIB 
201 International Study Group. Lancet. 1997;350(9086):1193–1198.
12. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of 
acute cellular rejection among renal allograft recipients treated with 
basiliximab, a chimeric anti-interleukin-2-receptor monoclonal anti-
body. United States Simulect Renal Study Group. Transplantation. 
1999;67(2):276–284.
13. Kovarik J, Wolf P, Cisterne JM, et al. Disposition of basiliximab, an 
interleukin-2 receptor monoclonal antibody, in recipients of mismatched 
cadaver renal allografts. Transplantation. 1997;64(12):1701–1705.
Biologics: Targets & Therapy 2009:3334
Sageshima et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
14. Kovarik JM, Kahan BD, Rajagopalan PR, et al. Population 
pharmacokinetics and exposure-response relationships for basiliximab 
in kidney transplantation. The US Simulect Renal Transplant Study 
Group. Transplantation. 1999;68(9):1288–1294.
15. Kovarik JM, Offner G, Broyer M, et al. A rational dosing algorithm 
for basiliximab (Simulect) in pediatric renal transplantation 
based on pharmacokinetic-dynamic evaluations. Transplantation. 
2002;74(7):966–971.
16. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor 
blockade with daclizumab to prevent acute rejection in renal 
transplantation. Daclizumab Triple Therapy Study Group. N Engl J 
Med. 1998;338(3):161–165.
17. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute 
renal allograft rejection by daclizumab. Daclizumab Double Therapy 
Study Group. Transplantation. 1999;67(1):110–115.
18. Ahsan N, Holman MJ, Jarowenko MV, Razzaque MS, Yang HC. 
Limited dose monoclonal IL-2R antibody induction protocol after pri-
mary kidney transplantation. Am J Transplant. 2002;2(6):568–573.
19. ter Meulen CG, Baan CC, Hene RJ, Hilbrands LB, Hoitsma AJ. Two 
doses of daclizumab are sufficient for prolonged interleukin-2Ralpha 
chain blockade. Transplantation. 2001;72(10):1709–1710.
20. Vincenti F, Pace D, Birnbaum J, Lantz M. Pharmacokinetic and 
pharmacodynamic studies of one or two doses of daclizumab in renal 
transplantation. Am J Transplant. 2003;3(1):50–52.
21. ter Meulen CG, van Riemsdijk I, Hene RJ, et al. Steroid-withdrawal 
at 3 days after renal transplantation with anti-IL-2 receptor alpha 
therapy: a prospective, randomized, multicenter study. Am J Transplant. 
2004;4(5):803–810.
22. Vincenti F, Lantz M, Birnbaum J, et al. A phase I trial of human-
ized anti-interleukin 2 receptor antibody in renal transplantation. 
Transplantation. 1997;63(1):33–38.
23. Summary of product characteristics for Zenapax (dacliximab). 1997:
Report no. RO 24-7375.
24. Strehlau J, Pape L, Offner G, Nashan B, Ehrich JH. Interleukin-2 recep-
tor antibody-induced alterations of ciclosporin dose requirements in 
paediatric transplant recipients. Lancet. 2000;356(9238):1327–1328.
25. Sifontis NM, Benedetti E, Vasquez EM. Clinically significant drug 
interaction between basiliximab and tacrolimus in renal transplant 
recipients. Transplant Proc. 2002;34(5):1730–1732.
26. Kovarik JM, Pescovitz MD, Sollinger HW, et al. Differential 
influence of azathioprine and mycophenolate mofetil on the 
disposition of basiliximab in renal transplant patients. Clin Transplant. 
2001;15(2):123–130.
27. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a 
chimeric interleukin-2 receptor (CD25) monoclonal antibody used 
in cadaveric renal transplantation. Transplantation. 1995;60(7): 
748–756.
28. Thistlethwaite JR, Jr., Nashan B, Hall M, Chodoff L, Lin TH. Reduced 
acute rejection and superior 1-year renal allograft survival with basil-
iximab in patients with diabetes mellitus. The Global Simulect Study 
Group. Transplantation. 2000;70(5):784–790.
29. Ponticelli C, Yussim A, Cambi V, et al. A randomized, double-blind 
trial of basiliximab immunoprophylaxis plus triple therapy in kidney 
transplant recipients. Transplantation. 2001;72(7):1261–1267.
30. Ekberg H, Backman L, Tufveson G, Tyden G, Nashan B, Vincenti F. 
Daclizumab prevents acute rejection and improves patient survival post 
transplantation: 1 year pooled analysis. Transpl Int. 2000;13(2): 
151–159.
31. Bumgardner GL, Hardie I, Johnson RW, et al. Results of 3-year 
phase III clinical trials with daclizumab prophylaxis for prevention 
of acute rejection after renal transplantation. Transplantation. 
2001;72(5):839–845.
32. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 
receptor monoclonal antibodies in renal transplantation: meta-analysis 
of randomised trials. BMJ. 2003;326(7393):789.
33. Iverson AJ, Vick SC, Sarnacki CT, Wright FH Jr. Daclizumab in live 
donor renal transplantation. Transplant Proc. 2000;32(4):790–792.
34. Vincenti F, Monaco A, Grinyo J, et al. Rapid steroid withdrawal 
versus standard steroid therapy in patients treated with basiliximab, 
cyclosporine, and mycophenolate mofetil for the prevention 
of acute rejection in renal transplantation. Transplant Proc. 
2001;33(1–2):1011–1012.
35. Ciancio G, Miller A, Burke GW, et al. Daclizumab induction for primary 
kidney transplant recipients using tacrolimus, mycophenolate mofetil, 
and steroids as maintenance immunosuppression. Transplant Proc. 
2001;33(1–2):1013–1014.
36. Chowdhury S, Kode RK, Ranganna K, et al. Induction strategy using 
basiliximab combined with mycophenolate MMF and immediate low-
dose cyclosporin is steroid sparing and more effective than OKT3. 
Transplant Proc. 2001;33(1–2):1057–1058.
37. Chang GJ, Mahanty HD, Vincenti F, et al. A calcineurin inhibitor-
sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 
mAb provides effective immunosuppression in kidney transplant 
recipients with delayed or impaired graft function. Clin Transplant. 
2000;14(6):550–554.
38. Pisani F, Buonomonth O, Iaria G, et al. Preliminary results of a 
prospective randomized study of basiliximab in kidney transplantation. 
Transplant Proc. 2001;33(1–2):2032–2033.
39. Vincenti F. Daclizumab: novel biologic immunoprophylaxis for pre-
vention of acute rejection in renal transplantation. Transplant Proc. 
1999;31(6):2206–2207.
40. Lawen JG, Davies EA, Mourad G, et al. Randomized double-blind study 
of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 
receptor monoclonal antibody, in combination with mycophenolate 
mofetil-containing triple therapy in renal transplantation. Transplantation. 
2003;75(1):37–43.
41. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleu-
kin 2 receptor antagonists for renal transplant recipients: a meta-analysis 
of randomized trials. Transplantation. 2004;77(2):166–176.
42. Ciancio G, Burke GW, Suzart K, et al. The use of daclizumab, 
tacrolimus and mycophenolate mofetil in African-American and 
Hispanic first renal transplant recipients. Am J Transplant. 2003;3(8): 
1010–1016.
43. Ciancio G, Burke GW, Suzart K, et al. Effect of daclizumab, tacrolimus 
and mycophenolate mofetil in racial minority first renal transplant 
recipients. Transplant Proc. 2002;34(5):1617–1618.
44. Meier-Kriesche HU, Kaza H, Palekar SS, et al. The effect of dacli-
zumab in a high-risk renal transplant population. Clin Transplant. 
2000;14(5):509–513.
45. Meier-Kriesche HU, Palenkar SS, Friedman GS, Mulgaonkar SP, 
Goldblat MV, Kaplan B. Efficacy of Daclizumab in an African-
American and Hispanic renal transplant population. Transpl Int. 
2000;13(2):142–145.
46. Ciancio G, Mattiazzi A, Roth D, Kupin W, Miller J, Burke GW. The 
use of daclizumab as induction therapy in combination with tacrolimus 
and mycophenolate mofetil in recipients with previous transplants. Clin 
Transplant. 2003;17(5):428–432.
47. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial 
exploring calcineurin inhibitors avoidance in renal transplantation. 
Transplantation. 2001;71(9):1282–1287.
48. Tran HT, Acharya MK, McKay DB, et al. Avoidance of cyclosporine 
in renal transplantation: effects of daclizumab, mycophenolate mofetil, 
and steroids. J Am Soc Nephrol. 2000;11(10):1903–1909.
49. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with 
mycophenolate mofetil, daclizumab and corticosteroids in renal 
allograft recipients: the CAESAR Study. Am J Transplant. 2007;7(3): 
560–570.
50. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation 
without use of calcineurin inhibitors preserves renal structure and 
function at two years. Am J Transplant. 2004;4(11):1776–1785.
51. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with 
sirolimus and mycophenolate mofetil-based immunosuppression: 
5-year results of a randomized prospective trial compared to calcineurin 
inhibitor drugs. Transplantation. 2007;83(7):883–892.
Biologics: Targets & Therapy 2009:3 335
iL-2r antibodies in renal transplantationDovepress
submit your manuscript | www.dovepress.com
Dovepress 
52. Martinez-Mier G, Mendez-Lopez MT, Budar-Fernandez LF, et al. 
Living related kidney transplantation without calcineurin inhibi-
tors: initial experience in a Mexican center. Transplantation. 
2006;82(11):1533–1536.
53. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure 
to calcineurin inhibitors in renal transplantation. N Engl J Med. 
2007;357(25):2562–2575.
54. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T. Everolimus 
and reduced-exposure cyclosporine in de novo renal-transplant recipi-
ents: a three-year phase II, randomized, multicenter, open-label study. 
Transplantation. 2004;78(9):1332–1340.
55. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized 
cyclosporine dosing in renal transplant recipients: 6-month safety and 
efficacy results of two randomized studies. Am J Transplant. 2004;4(4): 
626–635.
56. Tedesco-Silva H Jr, Vitko S, Pascual J, et al. 12-month safety and 
efficacy of everolimus with reduced exposure cyclosporine in de novo 
renal transplant recipients. Transpl Int. 2007;20(1):27–36.
57. Hong JC, Kahan BD. A calcineurin antagonist-free induction strategy 
for immunosuppression in cadaveric kidney transplant recipients at risk 
for delayed graft function. Transplantation. 2001;71(9):1320–1328.
58. McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery 
from delayed graft function after cadaveric renal transplantation. Am J 
Transplant. 2003;3(4):416–423.
59. Boletis JN, Theodoropoulou H, Hiras T, et al. Monoclonal antibody 
basiliximab with low cyclosporine dose as initial immunosuppression. 
Transplant Proc. 2001;33(7–8):3184–3186.
60. Parrott NR, Hammad AQ, Watson CJ, Lodge JP, Andrews CD. 
Multicenter, randomized study of the effectiveness of basiliximab in 
avoiding addition of steroids to cyclosporine a monotherapy in renal 
transplant recipients. Transplantation. 2005;79(3):344–348.
61. Kamar N, Garrigue V, Karras A, et al. Impact of early or delayed 
cyclosporine on delayed graft function in renal transplant recipients: 
a randomized, multicenter study. Am J Transplant. 2006;6(5 Pt 1): 
1042–1048.
62. Mourad G, Karras A, Kamar N, et al. Renal function with delayed 
or immediate cyclosporine microemulsion in combination with 
enteric-coated mycophenolate sodium and steroids: results of follow 
up to 30 months post-transplant. Clin Transplant. 2007;21(3): 
295–300.
63. Andrés A, Marcén R, Valdés F, et al. NI2A Study Group. 
A randomized trial of basiliximab with three different patterns of 
cyclosporin A initiation in renal transplant from expanded criteria 
donors and at high risk of delayed graft function. Clin Transplant. 
2009;23(1):23–32.
64. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal 
transplant recipients with well-functioning grafts. The Canadian 
Multicentre Transplant Study Group. CMAJ. 1992;147(5):645–657.
65. Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in 
kidney transplant recipients on cyclosporine and mycophenolate 
mofetil – a prospective randomized study. Steroid Withdrawal Study 
Group. Transplantation. 1999;68(12):1865–1874.
66. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H. 
Double-blind comparison of two corticosteroid regimens plus mycophe-
nolate mofetil and cyclosporine for prevention of acute renal allograft 
rejection. Transplantation. 2000;70(9):1352–1359.
67. Pascual J, Quereda C, Zamora J, Hernandez D. Steroid withdrawal in 
renal transplant patients on triple therapy with a calcineurin inhibitor 
and mycophenolate mofetil: a meta-analysis of randomized, controlled 
trials. Transplantation. 2004;78(10):1548–1556.
68. Cole E, Landsberg D, Russell D, et al. A pilot study of steroid-free 
immunosuppression in the prevention of acute rejection in renal allograft 
recipients. Transplantation. 2001;72(5):845–850.
69. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter 
randomized prospective trial of steroid withdrawal in renal transplant 
recipients receiving basiliximab, cyclosporine microemulsion and 
mycophenolate mofetil. Am J Transplant. 2003;3(3):306–311.
70. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-free 
immunosuppression with tacrolimus, mycophenolate mofetil, and 
daclizumab induction in renal transplantation. Transplantation. 
2005;79(7):807–814.
71. Vitko S, Klinger M, Salmela K, et al. Two corticosteroid-free 
regimens-tacrolimus monotherapy after basiliximab administration 
and tacrolimus/mycophenolate mofetil-in comparison with a standard 
triple regimen in renal transplantation: results of the Atlas study. 
Transplantation. 2005;80(12):1734–1741.
72. Woodle ES,  Firs t  MR, Pirsch J ,  Shihab F,  Gaber  AO, 
Van Veldhuisen P. A prospective, randomized, double-blind, 
placebo-controlled multicenter trial comparing early (7 day) 
corticosteroid cessation versus long-term, low-dose corticosteroid 
therapy. Ann Surg. 2008;248(4):564–577.
73. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J. 
A randomized, multicenter study of steroid avoidance, early steroid 
withdrawal or standard steroid therapy in kidney transplant recipients. 
Am J Transplant. 2008;8(2):307–316.
74. Pascual J, Zamora J, Galeano C, Royuela A, Quereda C. Steroid 
avoidance or withdrawal for kidney transplant recipients. Cochrane 
Database Syst Rev. 2009(1):CD005632.
75. Woodle ES, Vincenti F, Lorber MI, et al. A multicenter pilot study 
of early (4-day) steroid cessation in renal transplant recipients under 
simulect, tacrolimus and sirolimus. Am J transplant. 2005;5(1): 
157–166.
76. Anil Kumar MS, Heifets M, Fyfe B, et al. Comparison of steroid avoid-
ance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus 
combination in kidney transplantation monitored by surveillance biopsy. 
Transplantation. 2005;80(6):807–814.
77. Kumar MS, Heifets M, Moritz MJ, et al. Safety and efficacy of steroid 
withdrawal two days after kidney transplantation: analysis of results 
at three years. Transplantation. 2006;81(6):832–839.
78. Gallon L, Perico N, Dimitrov BD, et al. Long-term renal 
allograft function on a tacrolimus-based, pred-free maintenance 
immunosuppression comparing sirolimus vs MMF. Am J Transplant. 
2006;6(7):1617–1623.
79. Montagnino G, Sandrini S, Iorio B, et al. A randomized exploratory 
trial of steroid avoidance in renal transplant patients treated with 
everolimus and low-dose cyclosporine. Nephrol Dial Transplant. 
2008;23(2):707–714.
80. Alloway RR, Hanaway MJ, Trofe J, et al. A prospective, pilot 
study of early corticosteroid cessation in high-immunologic-risk 
patients: the Cincinnati experience. Transplant Proc. 2005;37(2): 
802–803.
81. Anil Kumar MS, Moritz MJ, Saaed MI, et al. Avoidance of chronic 
steroid therapy in african american kidney transplant recipients 
monitored by surveillance biopsy: 1-year results. Am J Transplant. 
2005;5(8):1976–1985.
82. Anil Kumar MS, Khan S, Ranganna K, Malat G, Sustento-Reodica N, 
Meyers WC. Long-term outcome of early steroid withdrawal after 
kidney transplantation in African American recipients monitored by 
surveillance biopsy. Am J Transplant. 2008;8(3):574–585.
83. Nair MP, Nampoory MR, Johny KV, et al. Induction immuno-
suppression with interleukin-2 receptor antibodies (basiliximab 
and daclizumab) in renal transplant recipients. Transplant Proc. 
2001;33(5):2767–2769.
84. Lin M, Ming A, Zhao M. Two-dose basiliximab compared with 
two-dose daclizumab in renal transplantation: a clinical study. Clin 
Transplant. 2006;20(3):325–329.
85. Soltero L, Carbajal H, Sarkissian N, et al. A truncated-dose 
regimen of daclizumab for prevention of acute rejection in kidney 
transplant recipients: a single-center experience. Transplantation. 
2004;78(10):1560–1563.
86. Stratta RJ, Alloway RR, Lo A, Hodge EE. One-year outcomes 
in simultaneous kidney-pancreas transplant recipients receiving 
an alternative dosing regimen of daclizumab. Transplant Proc. 
2004;36(4):1080–1081.
Biologics: Targets & Therapy 2009:3
Biologics: Targets & Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/biologics-targets--therapy-journal
Biologics: Targets & Therapy is an international, peer-reviewed 
journal focusing on the patho-physiological rationale for and clinical 
application of Biologic agents in the management of autoimmune 
diseases, cancers or other pathologies where a molecular target can 
be identified. This journal is indexed on PubMed Central, CAS, 
EMBase, Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. 
Visit http://www.dovepress.com/testimonials.php to read real quotes 
from published authors.
336
Sageshima et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
87. Ciancio G, Burke GW, Suzart K, et al. Daclizumab induction, tacrolimus, 
mycophenolate mofetil and steroids as an immunosuppression 
regimen for primary kidney transplant recipients. Transplantation. 
2002;73(7):1100–1106.
88. Ciancio G, Burke GW, Suzart K, et al. Efficacy and safety of daclizumab 
induction for primary kidney transplant recipients in combination 
with tacrolimus, mycophenolate mofetil, and steroids as maintenance 
immunosuppression. Transplant Proc. 2003;35(2):873–874.
89. Kode R, Fa K, Chowdhury S, et al. Basiliximab plus low-dose cyclo-
sporin vs OKT3 for induction immunosuppression following renal 
transplantation. Clin Transplant. 2003;17(4):369–376.
90. Sollinger H, Kaplan B, Pescovitz MD, et al. Basiliximab versus anti-
thymocyte globulin for prevention of acute renal allograft rejection. 
Transplantation. 2001;72(12):1915–1919.
91. Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with 
basiliximab compared with antithymocyte globulin in renal transplant 
patients receiving MMF-containing triple therapy. Am J Transplant. 
2002;2(1):48–56.
92. Abou-Jaoude MM, Ghantous I, Almawi WY. Comparison of dacli-
zumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-
Fresenius induction therapy in kidney transplantation. Mol Immunol. 
2003;39(17–18):1083–1088.
93. Kyllonen LE, Eklund BH, Pesonen EJ, Salmela KT. Single bolus 
antithymocyte globulin versus basiliximab induction in kidney trans-
plantation with cyclosporine triple immunosuppression: efficacy and 
safety. Transplantation. 2007;84(1):75–82.
94. Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D. 
Sequential protocols using basiliximab versus antithymocyte globu-
lins in renal-transplant patients receiving mycophenolate mofetil and 
steroids. Transplantation. 2004;78(4):584–590.
 95. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit 
antithymocyte globulin versus basiliximab in renal transplantation. 
N Engl J Med. 2006;355(19):1967–1977.
 96. Brennan DC, Schnitzler MA. Long-term results of rabbit anti-
thymocyte globulin and basiliximab induction. N Engl J Med. 
2008;359(16):1736–1738.
 97. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, 
Stuart FP. Alemtuzumab induction and prednisone-free maintenance 
immunotherapy in kidney transplantation: comparison with basilix-
imab induction – long-term results. Am J Transplant. 2005;5(10): 
2539–2548.
 98. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three 
renal transplant induction antibodies: early comparison of tacrolimus, 
mycophenolate mofetil, and steroid dosing, and newer immune-
monitoring. Transplantation. 2005;80(4):457–465.
 99. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of thy-
moglobulin vs alemtuzumab (with lower dose maintenance immuno-
suppression) vs daclizumab in renal transplantation at 24 months of 
follow-up. Clin Transplant. 2008;22(2):200–210.
100. Vincenti F, Larsen C, Durrbach A, et al. Costimulation block-
ade with belatacept in renal transplantation. N Engl J Med. 
2005;353(8):770–781.
101. Ciancio G, Burke GW, Gaynor JJ, et al. Randomized trial of myco-
phenolate mofetil versus enteric-coated mycophenolate sodium in 
primary renal transplant recipients given tacrolimus and daclizumab/
thymoglobulin: one year follow-up. Transplantation. 2008;86(1):67–74.
102. United States Renal Data System 2007 Annual Data Report – 
Transplantation. Am J Kidney Dis. 2008;51(1):S155–S172.
